Bain & Company acquires minority stake in Trinity Life Sciences

18 August 2022 2 min. read

Bain & Company has entered a strategic partnership with Trinity Life Sciences, a Boston-based life sciences consulting firm. The partnership includes Bain acquiring a minority stake in Trinity.

Founded in 1996, Trinity is a leading advisor in life sciences commercialization, serving large global clients in biopharma and medtech. The firm offers corporate strategy, product planning and forecasting, portfolio strategy, business development support, market intelligence and benchmarking, and proprietary technology products in data and analytics.

Trinity has more than 1,600 people across offices in the US, Canada, Germany, the UK, and India.

The partnership will combine Trinity’s deep technical expertise in biopharma and medtech with Bain’s extensive global consulting experience across the life sciences value chain. Bain says the collaboration will create the most capable biopharma advisor in the industry.

Bain & Company acquires minority stake in Trinity Life Sciences

“The life sciences industry is fast growing and quickly evolving, requiring both breadth of experience and depth of expertise from its advisors,” said Tim van Biesen, the head of Bain & Company’s global healthcare practice. “This partnership delivers best-in-class capabilities to serve our clients’ comprehensive needs. By focusing on all relevant levels of life sciences organizations, we deliver the most tailored support and curated solutions to the questions and details that matter to each.”

Trinity in November recapitalized with Kohlberg & Company, a Mount Kisco, NY-based private equity firm specializing in leveraged buyouts. The transaction included the creation of a new 10-person board at Trinity.

A month before the Kohlberg transaction, Trinity acquired CBPartners, a New York-based boutique life sciences strategy consulting firm with more than 75 professionals.

“This partnership feels like a perfect match as we continue to expand and deepen our client offerings,” said David Fitzhenry, CEO of Trinity Life Sciences. “It brings together both companies’ industry-leading life sciences experts, our advanced data and analytics services, and Bain’s expansive capabilities—in areas such as private equity, M&A, commercial excellence and digital transformation—to serve projects that rise to the C-suite agenda.”